Company news

Racura Oncology Ltd news in 2022

Racura Oncology Ltd's news releases, calls and decks from 2022, newest first.

View company

Race supports Study of Extramedullary AML

December 22, 2022

Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO

December 15, 2022

Race Appoints Damian Clarke-Bruce as CEO & Managing Director

December 13, 2022

Positive Pre-IND Guidance from FDA on Zantrene

November 22, 2022

Response to ASX Price Query

October 18, 2022

Race Develops Improved IV Formulation of Zantrene

September 27, 2022

Race Initiates New Drug Discovery Program

September 26, 2022

Race Oncology: Update - Notification of buy-back - RAC

July 27, 2022

Race Oncology: RAC Quarterly Investor Presentation

July 27, 2022

Race Oncology: Quarterly Activity Report & Appendix 4C

July 21, 2022

Zantrene Protects Mouse Hearts from Chemotherapy Damage

June 29, 2022

Zantrene shows synergy with kinase inhibitors in melanoma

June 27, 2022

Zantrene Improves Immune Therapy Treatment of Melanoma

June 21, 2022

Race Oncology Announces On-Market Share Buyback

June 8, 2022

EMD AML MDS Trial Expands to Europe

June 7, 2022

Zantrene AML trial in Israel advances to Phase 2

May 27, 2022

Race Receives Governance Approval for AML EMD & MDS Trial

May 11, 2022

Race receives Human Ethics AML Trial Approval

April 6, 2022

Supply Agreement for EMD AML Trial

March 30, 2022

Zantrene highly effective in EMD AML Mouse Model

March 16, 2022

Race Oncology: ASX Small and Mid-Cap Conference Presentation

March 14, 2022

Compelling Zantrene Preclinical Kidney Cancer Data

March 9, 2022

Race Oncology: Application for quotation of securities - RAC

March 6, 2022

MD Anderson Preclinical AML Study on Zantrene Published

February 22, 2022

Decks in 2022